RNF144A enforces IL-2-STAT5 dominance over RAF-ERK-MAPK signaling in antiviral CD8 T cells 2309113
Abstract Introduction IL-2 is central to CD8 T cell responses and signals via JAK-STAT5, RAF-ERK-MAPK, and PI3K-AKT pathways, but how STAT5-dominant output is enforced from this shared receptor is unclear. We hypothesized that uncharacterized IL-2-induced, STAT5-regulated E3 ubiquitin ligases sculpt this signaling hierarchy to optimize antiviral CD8 T cell function. Methods RNA-seq of human CD8 T cells stimulated with IL-2 ± JAK inhibition plus STAT5 ChIP-seq identified IL-2/STAT5-regulated ubiquitin genes. Rnf144a-/- mice and mixed bone marrow chimeras were used to define CD8-intrinsic roles during influenza infection. RNF144A localization and substrates were mapped by biochemical and imaging assays, and whole-blood transcriptomes from patients with moderate or severe influenza were analyzed to relate RNF144A expression and gene signatures to clinical severity. Results IL-2 broadly remodeled the T cell ubiquitin program, with RNF144A emerging as the most strongly induced STAT5-bound E3 ligase. RNF144A localized to the plasma membrane, associated with IL-2Rβ and STAT5, and enhanced STAT5 recruitment and phosphorylation, sustaining STAT5-dependent transcription. In parallel, RNF144A acted as a bona fide E3 ligase that directly polyubiquitinated RAF1 for degradation, reducing ERK activation and thereby preserving JAK-STAT5 dominance over RAF-ERK-MAPK output. CD8 T cells from Rnf144a-/- mice showed impaired IL-2-induced effector gene expression, degranulation, and cytokine production, and CD8-intrinsic deficiency in mixed chimeras reduced antigen-specific responses and worsened weight loss and lung inflammation after influenza infection. In human influenza, RNF144A expression was reduced in severe disease, inversely correlated with an ERK-MAPK target gene signature, and discriminated severe from moderate cases with performance comparable to established severity markers. Conclusion RNF144A is an IL-2-STAT5-induced E3 ligase that enforces STAT5-dominant signaling and limits viral immunopathology. Funding Source N/A Topic Categories Immune Response Regulation: Molecular Mechanisms (IRM)
Authors
- Hiroyuki Nagashima (ORCID: https://orcid.org/0000-0001-8405-6746)
- Sangmi Kim (ORCID: https://orcid.org/0000-0002-1761-4696)
- Dhaneshwar Kumar (ORCID: https://orcid.org/0000-0003-3307-3065)
- Zu‐Xi Yu (ORCID: https://orcid.org/0000-0002-1341-4486)
- Claudia Kemper (ORCID: https://orcid.org/0000-0003-4196-1417)
- Majid Kazemian (ORCID: https://orcid.org/0000-0001-7080-8820)
- Behdad Afzali (ORCID: https://orcid.org/0000-0003-2968-1156)
- Bingyu Yan (ORCID: https://orcid.org/0000-0003-4429-8200)
- Tilo Freiwald (ORCID: https://orcid.org/0000-0002-4759-717X)
- Susan John (ORCID: https://orcid.org/0000-0003-3300-6954)
- Suman Mitra
- Marie-José Bijlmakers
- Estefanía Nova-Lamperti (ORCID: https://orcid.org/0000-0002-7673-0013)
- Arian Laurence
- John O’Shea
- Erin West
- Dragana Jankovic
- Nardos Cheru
- Alejandro Villarino
- Lauren Brinster
- Daniel Chauss
- Gregory Weitsman
- Nicolas Merle
Institutions
- National Institutes of Health (US)
- Inserm (FR)
- King's College London (GB)
- Purdue University West Lafayette (US)
- Université de Lille (FR)
- Stanford University (US)
Publication Details
- Journal
- The Journal of Immunology
- Published
- 2026-07-28
- DOI
- https://doi.org/10.1093/jimmun/vkag141.1499
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00